Chinese
Home
About Livzon
Milestones
Leaders' Caring
Company Honors
Cultural Vision
Contact Us
Media
Livzon News
Employment system
Investor Relations
Company Governance
Announcement
Financial Reports
ESG Report
Shareholder Returns
Stock Information
Sustainable Development
Human Development
Board Diversity Policy
Business Ethics
Supplier
Environment, Occupational Health and Safety (EHS)
Philanthropy
Privacy Policy
Tax policy
ESG Ratings and Honors
Product
Leading Products
Products List
ADR Reporting
R&D
R&D Platforms
Livzon microspheres
Livzon Bio
Livzon Research Institute
R&D Achievements
IP Achievements
Overseas Market
Overseas Business
Specialty Products
Certificates
Contact us
Join Us
Social Recruitment
Campus Recruitment
Compensation and Benefits
Appeal Against
Bidding procurement
Tender Announcement
Supplier Login
Supervision and Reporting
Contact information
Online message
ESG report
Shareholder returns
Stock information
Contacts
Letter to Registered Shareholders
File size:
372.1KB
File Type:
pdf
2026-04-23
VOLUNTARY ANNOUNCEMENT THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF JP-1366 TABLET
175.8KB
2026-04-10
Date of Board Meeting
184.3KB
2026-04-08
Monthly Return of Equity Issuer on Movements in Securities for the Month Ended 31 March 2026
67.6KB
2026-04-01
SUPPLEMENTAL ANNOUNCEMENT ON THE PROPOSED PROFIT DISTRIBUTION PLAN FOR THE YEAR ENDED 31 DECEMBER 2025
134.8KB
2026-03-26
VOLUNTARY ANNOUNCEMENT THE NOTICE OF DRUG CLINICAL TRIAL APPROVAL OF BREXPIPRAZOLE MICROSPHERES
176.0KB
ANNOUNCEMENT OF AUDITED RESULTS FOR THE YEAR ENDED 31 DECEMBER 2025
7.0MB
2026-03-25
Final Dividend for the year ended 31 December 2025
494.8KB
POSITIONS HELD BY CURRENT DIRECTORS AT THE BOARD AND THE BOARD COMMITTEES
151.9KB
APPOINTMENT OF MEMBERS OF THE STRATEGY COMMITTEE AND THE NOMINATION COMMITTEE OF THE BOARD
169.5KB
